Living with ATP13A2 Disorders and Long-Term Outlook
At a Glance
ATP13A2-related CLN12 disease is progressive, but its pace and symptoms vary widely. Planning early for mobility, thinking and behavior changes, swallowing and breathing safety, caregiver support, and future care can help protect comfort, dignity, and independence.
Living with a diagnosis of ATP13A2-related disease means preparing for a journey that is progressive and unique to every individual. While the condition is lifelong and the symptoms will change over time, many families find that proactive planning and a focus on quality of life help them navigate the challenges ahead [1][2].
Navigating Physical Changes
The long-term outlook for mobility varies depending on whether the disease follows the Kufor-Rakeb (parkinsonism) or SPG78 (spasticity) pattern.
- Gait and Balance: Most people will experience a gradual change in how they walk. This may be due to bradykinesia (slowness), spasticity (stiffness), or ataxia (lack of coordination) [3][1].
- Mobility Transitions: Many patients eventually transition to using mobility aids. Natural history data are based on small reports, so the rate of progression and long-term mobility outcomes vary widely and cannot be reliably predicted from a published average [4]. However, others with more aggressive forms may require a wheelchair sooner to prevent falls and maintain independence [5]. Fall-proofing the home, adjusting work or school accommodations, and seeking occupational therapy early can preserve independence safely.
- Energy Conservation: As movement becomes more effortful, learning “energy conservation” techniques—such as scheduling demanding tasks for times when medications are most effective—can help maintain daily activity [6].
Managing Cognitive and Emotional Well-being
Cognitive decline and psychiatric changes are a recognized part of the long-term clinical spectrum [7].
- Cognitive Support: Decline can range from mild forgetfulness to more significant dementia [3]. Using calendars, routine schedules, and simplified environments can help manage these changes.
- Psychiatric Stability: Behavioral outbursts or psychosis (hallucinations) may emerge as the disease progresses [8][9]. Early intervention with a neuropsychiatrist is key to keeping these symptoms from impacting the person’s safety or quality of life [8].
Safeguarding Nutrition and Breathing
As the muscles used for speaking and swallowing are affected, two major long-term health priorities emerge:
- Swallowing Safety: Difficulty swallowing (dysphagia) can lead to aspiration, where food or liquid enters the lungs [10]. Never change liquid consistencies or diet independently, as thickeners can reduce fluid intake and cause dehydration without guaranteeing the prevention of pneumonia. Interventions like upright positioning, supervision, specific oral care, and following an individualized swallowing plan from a Speech-Language Pathologist are key [11][10].
- Respiratory Health: In rare cases where the disease affects the muscles used for breathing, your medical team may recommend monitoring of lung function based on symptoms. Report red flags like breathlessness, weak cough, morning headaches, recurrent chest infections, or excessive daytime sleepiness promptly [12].
The Caregiver’s Journey
Because ATP13A2-related disease is a “family diagnosis,” caregiver support is not optional—it is a medical necessity. The increasing need for daily assistance, supervision for safety, and the emotional toll of cognitive changes can lead to significant burnout [8][13].
- Respite Care: Seeking help from professional caregivers or family members for even a few hours a week can provide essential rest.
- Future Planning: Engaging in “advanced care planning”—discussing medical wishes and financial/legal arrangements—while the patient can still participate fully in the conversation provides peace of mind for the entire family. Plan for long-term needs, such as driving assessments, managing the swallowing of medications, and eventual discussions about nutrition support (like a feeding tube) if swallowing becomes unsafe.
- Community: Connecting with rare disease organizations (like those for NCL or NBIA) can reduce the isolation that often comes with an ultra-rare diagnosis.
While the disease is progressive, the goal of modern medical care is to ensure that every stage of life is lived with as much comfort, dignity, and connection as possible [2][14].
Common questions in this guide
What is the long-term outlook for ATP13A2-related disease?
When should we consider a cane, walker, or wheelchair?
How should swallowing problems be managed in CLN12 disease?
Which breathing changes should be reported to the medical team?
How can cognitive or behavioral changes be supported?
What can caregivers do to prepare for the future?
Get notified when new evidence is published on CLN12 disease.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (14)
- 1
Motor Neuron Involvement in Two ATP13A2-Related Families: ALS And HSP-Like Phenotypes.
Khosravi S, Amini E, Emamikhah M, et al.
Movement disorders clinical practice 2025; (12(6)):852-857 doi:10.1002/mdc3.70027.
PMID: 40028680 - 2
Kufor-Rakeb Syndrome in a Guatemalan Patient With an ATP13A2 Gene Pathogenic Variant: A Case Report.
Méndez-Veras R, Urbizo A, Cabrera J, Boburg S
Case reports in genetics 2025; (2025()):6993134 doi:10.1155/crig/6993134.
PMID: 41306646 - 3
Loss-of-function mutations in the ATP13A2/PARK9 gene cause complicated hereditary spastic paraplegia (SPG78).
Estrada-Cuzcano A, Martin S, Chamova T, et al.
Brain : a journal of neurology 2017; (140(2)):287-305 doi:10.1093/brain/aww307.
PMID: 28137957 - 4
Estimation of Ambulation and Survival in Neurodegeneration with Brain Iron Accumulation Disorders.
Amini E, Rohani M, Lang AE, et al.
Movement disorders clinical practice 2024; (11(1)):53-62 doi:10.1002/mdc3.13933.
PMID: 38291840 - 5
A novel ATP13A2 variant causing complicated hereditary spastic paraplegia.
Zhang F, Liu P, Li J, et al.
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2024; (45(4)):1749-1753 doi:10.1007/s10072-024-07334-w.
PMID: 38252374 - 6
French guidelines for the diagnosis and management of pure hereditary spastic paraplegia.
Mania-Pâris L, Ewenczyk C, Nicolas G, et al.
Revue neurologique 2025; (181(6)):471-482 doi:10.1016/j.neurol.2025.05.001.
PMID: 40450402 - 7
Case Report: Novel ATP13A2 pathogenic variants associated with early-onset parkinsonism and a mini-review.
Affronte L, Pini A, Pizzoli C, et al.
Frontiers in genetics 2025; (16()):1588812 doi:10.3389/fgene.2025.1588812.
PMID: 40799219 - 8
Psychiatric Manifestations of ATP13A2 Mutations.
Balint B, Damasio J, Magrinelli F, et al.
Movement disorders clinical practice 2020; (7(7)):838-841 doi:10.1002/mdc3.13034.
PMID: 33033738 - 9
Successful treatment of psychosis in a patient with Kufor-Rakeb syndrome with low dose aripiprazole: a case report.
McNeil-Gauthier AL, Brais B, Rouleau G, et al.
Neurocase 2019; (25(3-4)):133-137 doi:10.1080/13554794.2019.1625928.
PMID: 31232173 - 10
Aspiration and silent aspiration in Niemann-Pick disease type C1: longitudinal findings from the NIH natural history study.
Solomon BI, Munoz AM, Borruso A, et al.
Orphanet journal of rare diseases 2026; (21(1)).
PMID: 42693440 - 11
Clinical and ultrastructural findings in an ataxic variant of Kufor-Rakeb syndrome.
Pietrzak A, Badura-Stronka M, Kangas-Kontio T, et al.
Folia neuropathologica 2019; (57(3)):285-294 doi:10.5114/fn.2019.88459.
PMID: 31588715 - 12
Mutations in ATP13A2 (PARK9) are associated with an amyotrophic lateral sclerosis-like phenotype, implicating this locus in further phenotypic expansion.
Spataro R, Kousi M, Farhan SMK, et al.
Human genomics 2019; (13(1)):19 doi:10.1186/s40246-019-0203-9.
PMID: 30992063 - 13
Action Myoclonus and Seizure in Kufor-Rakeb Syndrome.
Rohani M, Lang AE, Sina F, et al.
Movement disorders clinical practice 2018; (5(2)):195-199 doi:10.1002/mdc3.12570.
PMID: 30868101 - 14
Pallidal degenerations and related disorders: an update.
Jellinger KA
Journal of neural transmission (Vienna, Austria : 1996) 2022; (129(5-6)):521-543 doi:10.1007/s00702-021-02392-2.
PMID: 34363531
This page is for informational purposes only and does not constitute medical advice. Your neurology and supportive-care teams can tailor mobility, swallowing, breathing, and future-planning recommendations to your situation.